Accessibility Menu
Provectus Biopharmaceuticals logo

Provectus Biopharmaceuticals(OTC) PVCT

Market Cap$25.22MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2002)-95%
5 Year-13%
1 Year-20%
1 Month-10%
$0.06
-0.17%
-0.00Today
Provectus Biopharmaceuticals last closing stock price
MetricPriceDate
Last closeUSD 0.062026-07-27
Provectus Biopharmaceuticals stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0.54%USD 0.062026-07-20
1 month-9.91%USD 0.072026-06-26
3 month+17.65%USD 0.052026-04-28
Year to date+7.33%USD 0.062025-12-31
1 year-20%USD 0.082025-07-25
3 year-45.45%USD 0.112023-07-28
5 year-13.04%USD 0.072021-07-28
Since inception-94.55%USD 1.102002-04-24

Provectus Biopharmaceuticals Financials at a Glance

Market Cap

$25.22MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$57.48K

Net Income (TTM)

-$5.62M

EPS (TTM)

-$0.01

P/E Ratio

-4.51

Dividend

$0.00

Beta (Volatility)

0.25 (Low)

Price

$0.06

Volume

78,269

Open

$0.06

Previous Close

$0.06

Daily Range

$0.06 - $0.06

52-Week Range

$0.04 - $0.11

Estimated Earnings Date

May 13, 2026

PVCT News

Lowe's store

Shorts Are Piling Into These Stocks. Should You Be Worried?

Sean WilliamsJun 16, 2014

3 Stocks Crushed by the Market Last Week

Keith SpeightsMay 28, 2014

63% Implosion: The Epic Collapse of Provectus Biopharmaceuticals, Inc

Dave WilliamsonMay 27, 2014

5 of Last Week's Biggest Losers

Rick MunarrizMay 25, 2014
8411757793_bce49074bf_z

This Week in Biotech: PTC Therapeutics Surprises, Isis' Data Dazzles, and Provectus Sinks

Sean WilliamsMay 24, 2014

Why Provectus Biopharmaceuticals Inc. Shares Plummeted

Sean WilliamsMay 22, 2014

3 Humongous Health-Care Stocks This Week

Keith SpeightsDec 28, 2013

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Provectus Biopharmaceuticals

Provectus develops medicines for cancer and skin diseases. Its main products aim to help patients with hard-to-treat tumors and chronic skin conditions. These treatments target people with limited options, offering new approaches for serious health problems.

Lab Bench to Bedside: What Provectus Makes

  • Oncology (PV-10): Investigational cancer therapy for adult and pediatric solid tumors; 100% of revenue from grants, not sales.
  • Oral Rose Bengal Sodium: Experimental oral drug for various adult and pediatric cancers; no commercial sales yet.
  • Dermatology (PH-10): Investigational topical treatment for inflammatory skin diseases like psoriasis and eczema.
  • Ophthalmology (PV-305): Topical drug candidate for eye infections, developed through subsidiary VisiRose.
  • Other Indications: Early-stage research for coronavirus, drug-resistant bacteria, wound healing, and animal health.

Growth Spurts and Side Quests

  • Launched VisiRose in 2024, partnering with University of Miami for eye disease research.
  • Expanded clinical trials for PV-10 in new cancer types in 2025.
  • Extended Knoxville office lease through June 2028 to support ongoing operations.
  • Published new research with Moffitt Cancer Center and University of Calgary in 2025.
  • No major acquisitions or global market entries reported as of 2025.

Provectus: The Secret Sauce

Provectus uses a patented process to make high-purity rose bengal sodium, a unique chemical for its drug candidates. The company holds patents covering its manufacturing and drug uses, with expiration dates into the 2040s. It collaborates with academic centers for research and follows strict manufacturing standards.

Five Things You Need to Know

  • All 2025 revenue came from grants, down 45.5% from 2024.
  • No approved products or commercial sales as of December 2025.
  • Net loss was $5.5 million in 2025, up 15.6% from 2024.
  • Cash balance fell to $251,291 at year-end 2025, down 49% year-over-year.
  • Company faces a $6.3 million working capital deficit and needs new funding.

Bottom Line

Provectus remains a small, research-focused biotech with no commercial products. Its future depends on successful trials and securing new funding.

AI Generated • Apr 16, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

6

CEO

Edward V. Pershing, CPA

Website

www.provectusbio.com

Headquarters

Knoxville, TN 37932, US

PVCT Financials

Key Financial Metrics (TTM)

Gross Margin

96.76%

Operating Margin

-8867.49%

Net Income Margin

-9775.33%

Return on Equity

89.65%

Return on Capital

N/A

Return on Assets

-972.83%

Earnings Yield

-22.17%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$25.22MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

420.28M

Volume

78.27K

Avg. Volume

175.40K

Financials (TTM)

Gross Profit

$55.62K

Operating Income

-$5.10M

EBITDA

-$5.10M

Operating Cash Flow

-$2.59M

Capital Expenditure

$5.00

Free Cash Flow

-$2.59M

Cash & ST Invst.

$223.88K

Total Debt

$2.77M

Provectus Biopharmaceuticals Performance Analysis

Provectus Biopharmaceuticals annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 989,042N/A
20232023-12-31USD 557,710-43.6%
20242024-12-31USD 617,14010.7%
20252025-12-31USD 336,108-45.5%
Provectus Biopharmaceuticals sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30-79.4%
Q32025-09-30-100.0%
Q42025-12-31N/A
Q12026-03-31N/A
Provectus Biopharmaceuticals annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -0.01-37.5%
20232023-12-31USD -0.01-12.9%
20242024-12-31USD -0.0152.7%
20252025-12-31USD -0.0114.2%
Provectus Biopharmaceuticals sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30-59.3%
Q32025-09-3027.9%
Q42025-12-319.7%
Q12026-03-31-10.7%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$0.00

-100.0%

Gross Profit

-$466.00

+99.5%

Gross Margin

0.00%

N/A

Market Cap

$25.22MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$4.20M

N/A

Employees

6

N/A

Net Income

-$1.29M

-13.2%

EBITDA

-$1.10M

-0.6%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$223.88K

-42.7%

Total Debt

$2.77M

+7.4%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$66.65K

N/A

Short Term Debt

$2.70M

+4.8%

Return on Assets

-9.73%

N/A

Return on Invested Capital

76.48%

N/A

Free Cash Flow

-$357.57K

+67.3%

Operating Cash Flow

-$357.57K

+67.3%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
DTCFFDefence Therapeutics Inc.
$0.29+9.96%
SEOVFSernova Corp.
$0.08-2.57%
MBXBFMicrobix Biosystems Inc.
$0.23+5.48%
MMIRFMedMira Inc.
$0.01-67.50%

Trending Stocks

Symbol / CompanyPricePrice Chg
NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF
$5.21-0.01%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$7.08-0.02%
JBLUJetBlue Airways
$5.95+0.10%
MARAMara Holdings
$11.27-0.04%

Questions About PVCT

What is the current price of Provectus Biopharmaceuticals?

Provectus Biopharmaceuticals is trading at $0.06 per share.

What is the 52-week range for Provectus Biopharmaceuticals?

Over the past 52 weeks, Provectus Biopharmaceuticals has traded between $0.04 and $0.11.

How much debt does Provectus Biopharmaceuticals have?

As of the most recent reporting period, Provectus Biopharmaceuticals reported total debt of $2.77M.

How much cash does Provectus Biopharmaceuticals have on hand?

Provectus Biopharmaceuticals reported $223.88K in cash and cash equivalents in its most recent financial results.

What is Provectus Biopharmaceuticals’s dividend yield?

Provectus Biopharmaceuticals does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services